Axel Grothey, MD

Articles

Dr. Grothey on the Potential Role of ctDNA as a Marker for Rechallenging Treatment in CRC

May 14th 2021

Axel Grothey, MD, discusses the potential utility of circulating tumor DNA as a marker for rechallenging patients with treatment in colorectal cancer.

Dr. Grothey on the Potential Role of ctDNA in Screening for CRC

May 5th 2021

Axel Grothey, MD, discusses the potential role of circulating tumor DNA testing in screening patients for early-stage colorectal cancer.

Dr. Grothey on the Differences Between Available ctDNA Assays in CRC

March 29th 2021

Axel Grothey, MD, discusses the differences between available assays evaluating circulating tumor DNA in colorectal cancer.

Dr. Grothey on the Potential Utility of TAS-102/Bevacizumab in Metastatic CRC

March 8th 2021

Axel Grothey, MD, discusses the potential utility of trifluridine/tipiracil in combination with bevacizumab in metastatic colorectal cancer.

Dr. Grothey on Dosing Strategies With Regorafenib in CRC

March 3rd 2021

Axel Grothey, MD, discusses dosing strategies with regorafenib in colorectal cancer.

Dr. Grothey on the Rationale to Evaluate Patritumab Deruxtecan in HER3+ CRC

February 16th 2021

Axel Grothey, MD, discusses the rationale to evaluate patritumab deruxtecan in HER3-positive colorectal cancer.

Dr. Grothey on Potential Combinations With Trastuzumab Deruxtecan in GI Malignancies

February 11th 2021

Axel Grothey, MD, discusses potential combination strategies with fam-trastuzumab deruxtecan-nxki in gastrointestinal malignancies.

Dr. Grothey on the Results of the ANCHOR-CRC Trial in BRAF V600E-Mutant mCRC

January 4th 2021

Axel Grothey, MD, discusses the results of the phase 2 ANCHOR-CRC trial in patients with BRAF-mutant metastatic colorectal cancer.

Dr. Grothey on the DESTINY-CRC01 Trial With Trastuzumab Deruxtecan in HER2+ CRC

December 22nd 2020

Axel Grothey, MD, discusses the DESTINY-CRC01 trial in patients with HER2-positive colorectal cancer.

Dr. Grothey on the Role of Precision Medicine in CRC

December 16th 2020

Axel Grothey, MD, discusses the role of precision medicine in colorectal cancer.